迪安诊断2月3日获融资买入1.07亿元，融资余额8.50亿元

Core Viewpoint - Dian Diagnostics has experienced significant fluctuations in its stock performance and financial metrics, indicating potential investment opportunities and risks in the medical diagnostics sector. Group 1: Stock Performance - On February 3, Dian Diagnostics' stock rose by 6.69%, with a trading volume of 1.084 billion yuan [1] - The financing buy-in amount for Dian Diagnostics on the same day was 107 million yuan, while the financing repayment was 91.08 million yuan, resulting in a net financing buy of 15.61 million yuan [1] - As of February 3, the total financing and securities lending balance for Dian Diagnostics was 854 million yuan, with the financing balance accounting for 5.50% of the circulating market value, indicating a high level compared to the past year [1] Group 2: Financial Performance - For the period from January to September 2025, Dian Diagnostics reported a revenue of 7.566 billion yuan, a year-on-year decrease of 18.28% [2] - The net profit attributable to shareholders for the same period was 56.7048 million yuan, reflecting a year-on-year decline of 56.67% [2] Group 3: Shareholder and Dividend Information - Since its A-share listing, Dian Diagnostics has distributed a total of 1.099 billion yuan in dividends, with 712 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders for Dian Diagnostics was 45,700, a decrease of 5.45% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 10.5635 million shares, a reduction of 4.235 million shares from the previous period [3]